An exploratory study of sunitinib in combination with docetaxal and trastuzumab as first-line therapy for HER-2 positive metastatic breast cancer. The breast, Dec. 2012, Vol. 21(6), p.716-23.
Cardoso, F., et al.
http://www.thebreastonline.com/article/PIIS0960977612001889/abstract?rss=yes
This exploratory study assessed the safety, pharmacokinetics, and antitumor activity of sunitinib combined with docetaxel and trastuzumab.
